Firmagon (degarelix) is a GnRH-antagonist for treatment of progressive hormone dependent prostate cancer.
Degarelix, compared with a GnRH-antagonist (leuprolid/leuprorelin), suppresses testosterone and PSA-levels within 3 days, without an increase in s-testosterone levels. Additional therapy with an antiandrogen is therefore not necessary in the first month of therapy. After 28 days both treatments suppress s-testosterone and s-PSA equally. The clinical value of the fast response has not been studied.
There was significant more reactions at the injection site as well as shivers with degarelix, and significant fewer arthralgias and UVI, as compared with leuprolid.
The price for one year of treatment with Firmagon corresponds to the price of 1 year of treatment with a GnRH-antagonist along with antiandrogen therapy (21.200 DKr against 21.500 DKr).
IRF states, that degarelix could be used if a rapid s-testosterone response is desired. However the clinical advantage of the effect of degarelix compared with leuprolid/leuproelin + antiandrogen in the initial phase is not known.
Firmagon was marketed the 18th of May 2009.